Jian Zhang

8PUBLICATIONS
14CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersWomen's studies (incl. girls' studies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 15, 2026
Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.

Rujiao Liu, Hui Jing, Yang Chen

|Jun 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

Herui Yao, Min Yan, Zhongsheng Tong

|Mar 08, 2024
Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study.

Doudou Li, Yizi Jin, Mingxi Lin

|Dec 01, 2023
HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial.

Quchang Ouyang, Ying Wang, Jian Zhang

|Nov 07, 2023
HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis.

Mingxi Lin, Ting Luo, Yizi Jin

|Oct 20, 2023
Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.

Yuxin Mu, Yanchun Meng, Yiqun Du

Pageof 2

Frequent Collaborators

2 joint publications

Yizi Jin

1 joint publications

Mingxi Lin

1 joint publications

Xichun Hu

1 joint publications

Herui Yao